MTNB - Matinas BioPharma Holdings Inc Stock Price, Fair Value and News

0.17USD0.00 (0.00%)Delayed

Market Summary

USD0.170.00

Delayed

0.00%

MTNB Stock Price

View Fullscreen

MTNB RSI Chart

MTNB Valuation

Market Cap

42.6M

Price/Earnings (Trailing)

-1.83

Price/Sales (Trailing)

38.9

Price/Free Cashflow

-2.48

MTNB Price/Sales (Trailing)

MTNB Profitability

Return on Equity

-159.73%

Return on Assets

-118.58%

Free Cashflow Yield

-40.29%

MTNB Fundamentals

MTNB Revenue

Revenue (TTM)

1.1M

Rev. Growth (Yr)

-100%

MTNB Earnings

Earnings (TTM)

-23.3M

Earnings Growth (Yr)

-5.64%

Earnings Growth (Qtr)

-9.6%

Breaking Down MTNB Revenue

Last 7 days

-5.6%

Last 30 days

-10.5%

Last 90 days

-26.1%

Trailing 12 Months

-58.7%

How does MTNB drawdown profile look like?

MTNB Financial Health

Current Ratio

5.15

MTNB Investor Care

Shares Dilution (1Y)

15.44%

Diluted EPS (TTM)

-0.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	4.3M	3.2M	2.2M	1.1M
2022	0	0	0	3.2M
2021	0	0	0	0
2020	0	0	0	0
2019	0	179.6K	89.8K	89.8K
2018	164.7K	209.6K	164.7K	119.8K
2017	151.8K	119.7K	104.8K	149.7K
2015	0	0	0	194.5K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Matinas BioPharma Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 22, 2022	conrad herbert j	gifted	-	-	1,358,120	-
Jun 22, 2022	conrad herbert j	gifted	-	-	-1,358,120	-
Dec 31, 2021	wikler matthew	acquired	-	-	7,859	-
Sep 30, 2021	wikler matthew	acquired	-	-	6,106	-
Sep 03, 2021	mannino raphael j	acquired	-	-	462,150	chief scientific officer
Aug 04, 2021	conrad herbert j	gifted	-	-	494,622	-
Aug 04, 2021	conrad herbert j	gifted	-	-	-494,622	-
Jul 07, 2021	conrad herbert j	gifted	-	-	-1,280,920	-
Jul 07, 2021	conrad herbert j	gifted	-	-	1,280,920	-
Jun 30, 2021	wikler matthew	acquired	-	-	10,244	-

Which funds bought or sold MTNB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	National Wealth Management Group, LLC	unchanged	-	2,288	11,314	0.01%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	47,644	35,135	35,193	-%
May 15, 2024	Bayesian Capital Management, LP	sold off	-100	-4,065	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-26.84	-708	7,913	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-4,127	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-72.54	-13,681	7,182	-%
May 15, 2024	Royal Bank of Canada	added	44.43	1,000	3,000	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	167	824	-%
May 15, 2024	MORGAN STANLEY	added	72.75	6,928	12,874	-%
May 15, 2024	STATE STREET CORP	reduced	-7.38	24,789	178,825	-%

Are Funds Buying or Selling MTNB?

Are funds buying MTNB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MTNB

No. of Funds

Unveiling Matinas BioPharma Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2022	boxer capital, llc	0.0%	0	SC 13G/A
Feb 16, 2021	boxer capital, llc	5.8%	11,478,634	SC 13G/A
Feb 12, 2021	vivo capital ix, llc	0.6%	1,176,974	SC 13G/A
Feb 14, 2020	boxer capital, llc	6.3%	10,188,312	SC 13G/A
Feb 13, 2020	vivo capital ix, llc	0.9%	1,826,015	SC 13G/A

Recent SEC filings of Matinas BioPharma Holdings Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 05, 2024	8-K	Current Report
Apr 04, 2024	424B5	Prospectus Filed
Mar 28, 2024	8-K	Current Report
Mar 27, 2024	8-K	Current Report
Mar 27, 2024	10-K	Annual Report
Mar 25, 2024	8-K	Current Report
Mar 22, 2024	8-K	Current Report
Mar 22, 2024	8-K	Current Report

Peers (Alternatives to Matinas BioPharma Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Matinas BioPharma Holdings Inc News

Latest updates

Matinas BioPharma Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q4	2020Q3	2019Q4	2019Q4	2019Q3	2019Q2	2018Q4	2018Q3
Revenue	-	-	-	-	-	1,096	1,063	1,063	1,063	532	-	19.00	38.00	57.00	77.00	96.00	64.00	32.00	-	90.00	-	-
Costs and Expenses	0.3%	5,902	5,887	6,134	6,159	6,682	6,543	6,525	6,988	6,714	6,878	4,790	6,386	6,551	-	5,700	5,736	-	4,561	4,610	4,167	2,954
S&GA Expenses	-100.0%	-	2,222	2,839	2,600	2,712	2,677	2,818	2,861	2,474	2,257	2,309	3,145	3,026	-	2,364	2,316	-	1,890	1,782	2,474	1,575
R&D Expenses	-6.0%	3,446	3,665	3,295	3,559	3,970	3,867	3,707	4,127	4,240	4,621	2,481	3,241	3,526	-	3,336	3,420	-	2,671	2,829	1,692	1,380
Net Income	-9.6%	-5,824	-5,314	-6,055	-6,060	-5,513	-3,634	-5,462	-5,923	-6,699	-6,836	-4,791	-4,956	-6,340	-	-5,449	-5,572	-	-4,404	-3,344	-3,626	-2,935
Net Income Margin	-1.4%	-21.22*	-20.93*	-9.85*	-6.41*	-4.79*	-6.59*	-267.92*	-283.22*	-259.24*	-255.25*	-239.81*	-248.93*	-	-	-	-	-	-	-	-	-
Free Cashflow	-26.0%	-5,769	-4,579	-4,435	-2,235	-4,129	-4,341	-5,220	-5,186	-3,993	-5,973	-864	-4,651	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-21.9%	20.00	25.00	30.00	34.00	38.00	45.00	48.00	52.00	56.00	61.00	67.00	70.00	72.00	71.00	75.00	79.00	84.00	40.00	45.00	48.00	51.00
Current Assets	-33.8%	10.00	16.00	20.00	24.00	28.00	35.00	37.00	42.00	45.00	51.00	56.00	61.00	63.00	62.00	65.00	69.00	74.00	30.00	34.00	37.00	40.00
Cash Equivalents	-77.6%	1.00	5.00	6.00	10.00	6.00	7.00	11.00	10.00	19.00	21.00	25.00	30.00	23.00	12.00	7.00	15.00	10.00	22.00	33.00	37.00	39.00
Net PPE	-4.9%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-13.8%	5.00	6.00	7.00	6.00	6.00	8.00	9.00	10.00	8.00	9.00	9.00	7.00	6.00	7.00	7.00	6.00	7.00	7.00	7.00	8.00	8.00
Current Liabilities	-23.8%	2.00	3.00	3.00	3.00	2.00	4.00	5.00	5.00	4.00	4.00	4.00	4.00	2.00	4.00	3.00	2.00	3.00	3.00	3.00	3.00	3.00
Shareholder's Equity	-24.4%	15.00	19.00	23.00	28.00	33.00	37.00	39.00	43.00	48.00	52.00	58.00	63.00	67.00	64.00	68.00	73.00	78.00	33.00	38.00	40.00	43.00
Retained Earnings	-3.3%	-181	-175	-170	-164	-158	-152	-149	-143	-137	-131	-124	-118	-112	-107	-101	-95.72	-89.42	-84.38	-78.80	-73.81	-70.00
Additional Paid-In Capital	0.5%	196	195	194	193	191	190	189	187	186	184	183	181	175	167	165	164	163	113	113	105	103
Shares Outstanding	0.1%	217	217	217	217	217	217	217	217	217	216	215	205	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	76.00	-	-	-	165	-	-	-	160	-	-	-	142	-	-	-	112	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-26.0%	-5,769	-4,579	-4,419	-2,193	-4,087	-4,299	-4,970	-5,131	-4,756	-3,957	-5,749	-864	-4,651	-4,307	-5,226	-3,168	-4,664	-4,898	-4,073	-2,096	-3,023
Share Based Compensation	-21.8%	995	1,272	1,196	1,208	1,272	1,340	1,413	1,215	1,260	1,074	1,061	1,056	1,101	1,220	953	945	1,447	688	671	822	804
Cashflow From Investing	-32.4%	2,000	2,960	1,084	6,198	3,000	-42.00	5,750	-3,792	2,961	57.00	243	7,654	8,817	9,089	-2,780	7,991	-54,967	-5,605	-73.43	-317	-14.25
Cashflow From Financing	5400.0%	53.00	-1.00	-1.00	-1.00	-4.00	-5.00	-3.00	-6.00	93.00	8.00	-8.32	180	6,785	550	54.00	4.00	47,439	10.00	-19.53	-167	30,028

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MTNB Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Contract revenue		$ 1,096
Costs and Expenses:
Research and development	3,446	3,970
General and administrative	2,456	2,712
Total costs and expenses	5,902	6,682
Loss from operations	(5,902)	(5,586)
Other income, net	78	73
Net loss	$ (5,824)	$ (5,513)
Net loss per share - basic	$ (0.03)	$ (0.03)
Net loss per share - diluted	$ (0.03)	$ (0.03)
Weighted average common shares outstanding:
Weighted average common shares outstanding - basic	217,358,085	217,264,526
Weighted average common shares outstanding - diluted	217,358,085	217,264,526
Other comprehensive gain, net of tax
Unrealized gain on securities available-for-sale	$ 87	$ 229
Other comprehensive gain, net of tax	87	229
Comprehensive loss	$ (5,737)	$ (5,284)

MTNB Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,071	$ 4,787
Marketable debt securities	7,039	8,969
Restricted cash – security deposit	50	50
Prepaid expenses and other current assets	2,129	1,737
Total current assets	10,289	15,543
Non-current assets:
Leasehold improvements and equipment – net	1,829	1,923
Operating lease right-of-use assets – net	2,919	3,064
Finance lease right-of-use assets – net	20	21
In-process research and development	3,017	3,017
Goodwill	1,336	1,336
Restricted cash – security deposit	200	200
Total non-current assets	9,321	9,561
Total assets	19,610	25,104
Current liabilities:
Accounts payable	473	514
Accrued expenses	839	1,447
Operating lease liabilities – current	681	656
Financing lease liabilities – current	5	5
Total current liabilities	1,998	2,622
Non-current liabilities:
Deferred tax liability	341	341
Operating lease liabilities – net of current portion	2,697	2,877
Financing lease liabilities – net of current portion	16	18
Total non-current liabilities	3,054	3,236
Total liabilities	5,052	5,858
Stockholders’ equity:
Common stock par value $0.0001 per share, 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 217,482,830 and 217,264,526 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	22	22
Additional paid-in capital	196,067	195,018
Accumulated deficit	(181,397)	(175,573)
Accumulated other comprehensive loss	(134)	(221)
Total stockholders’ equity	14,558	19,246
Total liabilities and stockholders’ equity	$ 19,610	$ 25,104

About Matinas BioPharma Holdings Inc

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

CEO	Mr. Jerome D. Jabbour J.D.
WEBSITE	matinasbiopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	34

Matinas BioPharma Holdings Inc Frequently Asked Questions

What is the ticker symbol for Matinas BioPharma Holdings Inc? What does MTNB stand for in stocks?

MTNB is the stock ticker symbol of Matinas BioPharma Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Matinas BioPharma Holdings Inc (MTNB)?

As of Fri May 17 2024, market cap of Matinas BioPharma Holdings Inc is 42.64 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MTNB stock?

You can check MTNB's fair value in chart for subscribers.

What is the fair value of MTNB stock?

You can check MTNB's fair value in chart for subscribers. The fair value of Matinas BioPharma Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Matinas BioPharma Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MTNB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Matinas BioPharma Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether MTNB is over valued or under valued. Whether Matinas BioPharma Holdings Inc is cheap or expensive depends on the assumptions which impact Matinas BioPharma Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MTNB.

What is Matinas BioPharma Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MTNB's PE ratio (Price to Earnings) is -1.83 and Price to Sales (PS) ratio is 38.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MTNB PE ratio will change depending on the future growth rate expectations of investors.